In the Arginine Deaminase and Mesothelioma (ADAM) phase II trial, sixty-eight ASS1-deficient (as determined by IHC) MPM patients were enrolled and randomized 2:1 to receive ADI-PEG20 or best supportive care (BSC) as first or second line treatment. This evidence concerns the gene ASS1 and mesothelioma.